Skip to main content
Erschienen in: Infection 2/2014

01.04.2014 | Clinical and Epidemiological Study

Epidemiology of candidemia in Qatar, the Middle East: performance of MALDI-TOF MS for the identification of Candida species, species distribution, outcome, and susceptibility pattern

verfasst von: S. J. Taj-Aldeen, A. Kolecka, R. Boesten, A. Alolaqi, M. Almaslamani, P. Chandra, J. F. Meis, T. Boekhout

Erschienen in: Infection | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Bloodstream infections (BSIs) due to Candida spp. constitute the predominant group of hospital-based fungal infections worldwide. A retrospective study evaluated the performance of matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) for the identification of BSI Candida isolates. The epidemiology, risk factors, demographic features, species distribution, and clinical outcome associated with candidemia in patients admitted to a single tertiary-care hospital in Qatar, were analyzed.

Methods

A single-center, retrospective analysis covering the period from January 1, 2004 to December 31, 2010 was performed. Molecular identification used sequence analysis of the D1/D2 domains of the large subunit ribosomal DNA (LSU rDNA) and the ITS1/2 regions of the rDNA. MALDI-TOF MS-based identification of all yeast isolates was performed with the ethanol/formic acid extraction protocol according to Bruker Daltonics (Bremen, Germany). The susceptibility profiles of 201 isolates to amphotericin B, itraconazole, fluconazole, voriconazole, anidulafungin, caspofungin, posaconazole, and isavuconazole were tested using CLSI standard broth microdilution method (M27-A3 and M27 S4) guidelines. Statistical analyses were performed with the statistical package SPSS 19.0.

Results

A total of 187 patients with 201 episodes of candidemia were identified. Candida albicans was the most common species isolated (33.8 %; n = 68), whereas non-albicans Candida species represented 66.2 % (n = 133) of the episodes. The species distribution and outcome of candidemia showed a difference in the crude mortality between patients infected with C. albicans (n = 30; 45.5 %) and non-albicans Candida species. For example, C. parapsilosis candidemia was associated with the lowest mortality rate (40.6 %), and patients with other non-albicans species had the highest mortality rate (68–71.4 %). High mortality rates were observed among pediatric (<1 year of age) and elderly patients (>60 years of age). All strains showed low minimum inhibitory concentrations (MICs) (MIC90 of 0.063 μg/ml) to isavuconazole. The overall resistance to voriconazole in vitro antifungal activity was 2.5 %. C. glabrata (n = 38) had an MIC90 of 8 μg/ml for fluconazole. Most yeast isolates were susceptible to anidulafungin (>99.5 %) and 81.1 % to caspofungin. Resistance to anidulafungin was detected in 1/8 (12.5 %) isolates of C. orthopsilosis. According to new Clinical and Laboratory Standards Institute (CLSI) breakpoints, C. glabrata (n = 38) showed 100 % resistance, and 37/68 (54.4 %) C. albicans isolates were susceptible dose dependent (SDD) to caspofungin. Identification by MALDI-TOF MS was in 100 % concordance with molecular identification.

Conclusion

The Middle East epidemiology of candidemia has a unique species distribution pattern distinct from other parts of the globe. High mortality rates were observed among pediatric (<1 year of age) and elderly patients (>60 years of age). All strains were susceptible to isavuconazole. All isolates of C.glabrata were resistant to caspofungin based on M27 S4. MALDI-TOF MS is a highly useful method for the routine identification of yeast isolates in clinical setting to achieve successful therapeutic treatment.
Literatur
1.
Zurück zum Zitat Colombo AL, Guimarães T, Silva LR, de Almeida Monfardini LP, Cunha AK, Rady P, Alves T, Rosas RC. Prospective observational study of candidemia in São Paulo, Brazil: incidence rate, epidemiology, and predictors of mortality. Infect Control Hosp Epidemiol. 2007;28:570–6.PubMedCrossRef Colombo AL, Guimarães T, Silva LR, de Almeida Monfardini LP, Cunha AK, Rady P, Alves T, Rosas RC. Prospective observational study of candidemia in São Paulo, Brazil: incidence rate, epidemiology, and predictors of mortality. Infect Control Hosp Epidemiol. 2007;28:570–6.PubMedCrossRef
2.
Zurück zum Zitat Morgan J. Global trends in candidemia: review of reports from 1995–2005. Curr Infect Dis Rep. 2005;7:429–39.PubMedCrossRef Morgan J. Global trends in candidemia: review of reports from 1995–2005. Curr Infect Dis Rep. 2005;7:429–39.PubMedCrossRef
3.
4.
Zurück zum Zitat Sipsas NV, Lewis RE, Tarrand J, Hachem R, Rolston KV, Raad II, Kontoyiannis DP. Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001–2007): stable incidence but changing epidemiology of a still frequently lethal infection. Cancer. 2009;115:4745–52.PubMedCrossRef Sipsas NV, Lewis RE, Tarrand J, Hachem R, Rolston KV, Raad II, Kontoyiannis DP. Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001–2007): stable incidence but changing epidemiology of a still frequently lethal infection. Cancer. 2009;115:4745–52.PubMedCrossRef
5.
Zurück zum Zitat Zirkel J, Klinker H, Kuhn A, Abele-Horn M, Tappe D, Turnwald D, Einsele H, Heinz WJ. Epidemiology of Candida blood stream infections in patients with hematological malignancies or solid tumors. Med Mycol. 2012;50:50–5.PubMedCrossRef Zirkel J, Klinker H, Kuhn A, Abele-Horn M, Tappe D, Turnwald D, Einsele H, Heinz WJ. Epidemiology of Candida blood stream infections in patients with hematological malignancies or solid tumors. Med Mycol. 2012;50:50–5.PubMedCrossRef
6.
Zurück zum Zitat Sampaio Camargo TZ, Marra AR, Silva CV, Cardoso MF, Martino MD, Camargo LF, Correa L. Secular trends of candidemia in a tertiary care hospital. Am J Infect Control. 2010;38:546–51.PubMedCrossRef Sampaio Camargo TZ, Marra AR, Silva CV, Cardoso MF, Martino MD, Camargo LF, Correa L. Secular trends of candidemia in a tertiary care hospital. Am J Infect Control. 2010;38:546–51.PubMedCrossRef
7.
Zurück zum Zitat Das I, Nightingale P, Patel M, Jumaa P. Epidemiology, clinical characteristics, and outcome of candidemia: experience in a tertiary referral center in the UK. Int J Infect Dis. 2011;15:e759–63.PubMedCrossRef Das I, Nightingale P, Patel M, Jumaa P. Epidemiology, clinical characteristics, and outcome of candidemia: experience in a tertiary referral center in the UK. Int J Infect Dis. 2011;15:e759–63.PubMedCrossRef
8.
Zurück zum Zitat Chalmers C, Gaur S, Chew J, Wright T, Kumar A, Mathur S, Wan WY, Gould IM, Leanord A, Bal AM. Epidemiology and management of candidaemia—a retrospective, multicentre study in five hospitals in the UK. Mycoses. 2011;54:e795–800.PubMedCrossRef Chalmers C, Gaur S, Chew J, Wright T, Kumar A, Mathur S, Wan WY, Gould IM, Leanord A, Bal AM. Epidemiology and management of candidaemia—a retrospective, multicentre study in five hospitals in the UK. Mycoses. 2011;54:e795–800.PubMedCrossRef
9.
Zurück zum Zitat Horn DL, Neofytos D, Anaissie EJ, Fishman JA, Steinbach WJ, Olyaei AJ, Marr KA, Pfaller MA, Chang CH, Webster KM. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin Infect Dis. 2009;48:1695–703.PubMedCrossRef Horn DL, Neofytos D, Anaissie EJ, Fishman JA, Steinbach WJ, Olyaei AJ, Marr KA, Pfaller MA, Chang CH, Webster KM. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin Infect Dis. 2009;48:1695–703.PubMedCrossRef
10.
Zurück zum Zitat Chitasombat MN, Kofteridis DP, Jiang Y, Tarrand J, Lewis RE, kontoyiannis DP. Rare opportunistic (non-Candida, non-Cryptococcus) yeast bloodstream infections in patients with cancer. J Infect. 2012;64:68–75.PubMedCrossRef Chitasombat MN, Kofteridis DP, Jiang Y, Tarrand J, Lewis RE, kontoyiannis DP. Rare opportunistic (non-Candida, non-Cryptococcus) yeast bloodstream infections in patients with cancer. J Infect. 2012;64:68–75.PubMedCrossRef
11.
Zurück zum Zitat Mokaddas EM, Ramadan SA, Abo el Maaty SH, Sanyal SC. Candidemia in pediatric surgery patients. J Chemother. 2000;12:332–8.PubMedCrossRef Mokaddas EM, Ramadan SA, Abo el Maaty SH, Sanyal SC. Candidemia in pediatric surgery patients. J Chemother. 2000;12:332–8.PubMedCrossRef
12.
Zurück zum Zitat Al-Tawfiq JA. Distribution and epidemiology of Candida species causing fungemia at a Saudi Arabian hospital, 1996–2004. Int J Infect Dis. 2007;11:239–44.PubMedCrossRef Al-Tawfiq JA. Distribution and epidemiology of Candida species causing fungemia at a Saudi Arabian hospital, 1996–2004. Int J Infect Dis. 2007;11:239–44.PubMedCrossRef
13.
Zurück zum Zitat De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, Pappas PG, Maertens J, Lortholary O, Kauffman CA, Denning DW, Patterson TF, Maschmeyer G, Bille J, Dismukes WE, Herbrecht R, Hope WW, Kibbler CC, Kullberg BJ, Marr KA, Muñoz P, Odds FC, Perfect JR, Restrepo A, Ruhnke M, Segal BH, Sobel JD, Sorrell TC, Viscoli C, Wingard JR, Zaoutis T, Bennett JE; European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group; National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008;46:1813–21.PubMedCentralPubMedCrossRef De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, Pappas PG, Maertens J, Lortholary O, Kauffman CA, Denning DW, Patterson TF, Maschmeyer G, Bille J, Dismukes WE, Herbrecht R, Hope WW, Kibbler CC, Kullberg BJ, Marr KA, Muñoz P, Odds FC, Perfect JR, Restrepo A, Ruhnke M, Segal BH, Sobel JD, Sorrell TC, Viscoli C, Wingard JR, Zaoutis T, Bennett JE; European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group; National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008;46:1813–21.PubMedCentralPubMedCrossRef
14.
Zurück zum Zitat Okoli I, Oyeka CA, Kwon-Chung KJ, Theelen B, Robert V, Groenewald JZ, McFadden DC, Casadevall A, Boekhout T. Cryptotrichosporon anacardii gen. nov., sp. nov., a new trichosporonoid capsulate basidiomycetous yeast from Nigeria that is able to form melanin on niger seed agar. FEMS Yeast Res. 2007;7:339–50.PubMedCrossRef Okoli I, Oyeka CA, Kwon-Chung KJ, Theelen B, Robert V, Groenewald JZ, McFadden DC, Casadevall A, Boekhout T. Cryptotrichosporon anacardii gen. nov., sp. nov., a new trichosporonoid capsulate basidiomycetous yeast from Nigeria that is able to form melanin on niger seed agar. FEMS Yeast Res. 2007;7:339–50.PubMedCrossRef
15.
Zurück zum Zitat Clinical and Laboratory Standards Institute (CLSI). Reference method for broth dilution antifungal susceptibility testing of yeasts; Approved standard—Third edition. CLSI document M27-A3. Wayne: CLSI; 2008. Clinical and Laboratory Standards Institute (CLSI). Reference method for broth dilution antifungal susceptibility testing of yeasts; Approved standard—Third edition. CLSI document M27-A3. Wayne: CLSI; 2008.
16.
Zurück zum Zitat Clinical Laboratory Standards Institute (CLSI). Reference method for broth dilution antifungal susceptibility testing of yeasts; Fourth informational supplement. CLSI document M27-S4. Wayne: CLSI; 2012. Clinical Laboratory Standards Institute (CLSI). Reference method for broth dilution antifungal susceptibility testing of yeasts; Fourth informational supplement. CLSI document M27-S4. Wayne: CLSI; 2012.
17.
Zurück zum Zitat Pfaller MA, Andes D, Arendrup MC, Diekema DJ, Espinel-Ingroff A, Alexander BD, Brown SD, Chaturvedi V, Fowler CL, Ghannoum MA, Johnson EM, Knapp CC, Motyl MR, Ostrosky-Zeichner L, Walsh TJ. Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria. Diag Microbiol Infect Dis. 2011;70:330–43.CrossRef Pfaller MA, Andes D, Arendrup MC, Diekema DJ, Espinel-Ingroff A, Alexander BD, Brown SD, Chaturvedi V, Fowler CL, Ghannoum MA, Johnson EM, Knapp CC, Motyl MR, Ostrosky-Zeichner L, Walsh TJ. Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria. Diag Microbiol Infect Dis. 2011;70:330–43.CrossRef
18.
Zurück zum Zitat Diekema DJ, Messer SA, Boyken LB, Hollis RJ, Kroeger J, Tendolkar S, Pfaller MA. In vitro activity of seven systemically active antifungal agents against a large global collection of rare Candida species as determined by CLSI broth microdilution methods. J Clin Microbiol. 2009;47:3170–7.PubMedCentralPubMedCrossRef Diekema DJ, Messer SA, Boyken LB, Hollis RJ, Kroeger J, Tendolkar S, Pfaller MA. In vitro activity of seven systemically active antifungal agents against a large global collection of rare Candida species as determined by CLSI broth microdilution methods. J Clin Microbiol. 2009;47:3170–7.PubMedCentralPubMedCrossRef
19.
Zurück zum Zitat Ellis M, Hedstrom U, Jumaa P, Bener A. Epidemiology, presentation, management and outcome of candidemia in a tertiary care teaching hospital in the United Arab Emirates, 1995–2001. Med Mycol. 2003;41:521–8.PubMedCrossRef Ellis M, Hedstrom U, Jumaa P, Bener A. Epidemiology, presentation, management and outcome of candidemia in a tertiary care teaching hospital in the United Arab Emirates, 1995–2001. Med Mycol. 2003;41:521–8.PubMedCrossRef
20.
Zurück zum Zitat Clark TA, Slavinski SA, Morgan J, Lott T, Arthington-Skaggs BA, Brandt ME, Webb RM, Currier M, Flowers RH, Fridkin SK, Hajjeh RA. Epidemiologic and molecular characterization of an outbreak of Candida parapsilosis bloodstream infections in a community hospital. J Clin Microbiol. 2004;42:4468–72.PubMedCentralPubMedCrossRef Clark TA, Slavinski SA, Morgan J, Lott T, Arthington-Skaggs BA, Brandt ME, Webb RM, Currier M, Flowers RH, Fridkin SK, Hajjeh RA. Epidemiologic and molecular characterization of an outbreak of Candida parapsilosis bloodstream infections in a community hospital. J Clin Microbiol. 2004;42:4468–72.PubMedCentralPubMedCrossRef
21.
Zurück zum Zitat Ortega M, Marco F, Soriano A, Almela M, Martínez JA, López J, Pitart C, Mensa J. Candida species bloodstream infection: epidemiology and outcome in a single institution from 1991 to 2008. J Hosp Infect. 2011;77:157–61.PubMedCrossRef Ortega M, Marco F, Soriano A, Almela M, Martínez JA, López J, Pitart C, Mensa J. Candida species bloodstream infection: epidemiology and outcome in a single institution from 1991 to 2008. J Hosp Infect. 2011;77:157–61.PubMedCrossRef
23.
Zurück zum Zitat Tortorano AM, Prigitano A, Lazzarini C, Passera M, Deiana ML, Cavinato S, De Luca C, Grancini A, Lo Cascio G, Ossi C, Sala E, Montagna MT. A 1-year prospective survey of candidemia in Italy and changing epidemiology over one decade. Infection. 2013;41:655–62.PubMedCrossRef Tortorano AM, Prigitano A, Lazzarini C, Passera M, Deiana ML, Cavinato S, De Luca C, Grancini A, Lo Cascio G, Ossi C, Sala E, Montagna MT. A 1-year prospective survey of candidemia in Italy and changing epidemiology over one decade. Infection. 2013;41:655–62.PubMedCrossRef
24.
Zurück zum Zitat Pfaller M, Neofytos D, Diekema D, Azie N, Meier-Kriesche HU, Quan SP, Horn D. Epidemiology and outcomes of candidemia in 3648 patients: data from the prospective antifungal therapy (PATH Alliance®) registry, 2004–2008. Diag Microbiol Infect Dis. 2012;74:323–31.CrossRef Pfaller M, Neofytos D, Diekema D, Azie N, Meier-Kriesche HU, Quan SP, Horn D. Epidemiology and outcomes of candidemia in 3648 patients: data from the prospective antifungal therapy (PATH Alliance®) registry, 2004–2008. Diag Microbiol Infect Dis. 2012;74:323–31.CrossRef
25.
Zurück zum Zitat Trick WE, Fridkin SK, Edwards JR, Hajjeh RA, Gaynes RP; National Nosocomial Infections Surveillance System Hospitals. Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989–1999. Clin Infect Dis. 2002;35:627–30.PubMedCrossRef Trick WE, Fridkin SK, Edwards JR, Hajjeh RA, Gaynes RP; National Nosocomial Infections Surveillance System Hospitals. Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989–1999. Clin Infect Dis. 2002;35:627–30.PubMedCrossRef
26.
Zurück zum Zitat Malani A, Hmoud J, Chiu L, Carver PL, Bielaczyc A, Kauffman CA. Candida glabrata fungemia: experience in a tertiary care center. Clin Infect Dis. 2005;41:975–81.PubMedCrossRef Malani A, Hmoud J, Chiu L, Carver PL, Bielaczyc A, Kauffman CA. Candida glabrata fungemia: experience in a tertiary care center. Clin Infect Dis. 2005;41:975–81.PubMedCrossRef
27.
Zurück zum Zitat Pemán J, Cantón E, Quindós G, Eraso E, Alcoba J, Guinea J, Merino P, Ruiz-Pérez-de-Pipaon MT, Pérez-del-Molino L, Linares-Sicilia MJ, Marco F, García J, Roselló EM, Gómez-G-de-la-Pedrosa E, Borrell N, Porras A, Yagüe G; FUNGEMYCA Study Group. Epidemiology, species distribution and in vitro antifungal susceptibility of fungaemia in a Spanish multicentre prospective survey. J Antimicrob Chemother. 2012;67:1181–7.PubMedCrossRef Pemán J, Cantón E, Quindós G, Eraso E, Alcoba J, Guinea J, Merino P, Ruiz-Pérez-de-Pipaon MT, Pérez-del-Molino L, Linares-Sicilia MJ, Marco F, García J, Roselló EM, Gómez-G-de-la-Pedrosa E, Borrell N, Porras A, Yagüe G; FUNGEMYCA Study Group. Epidemiology, species distribution and in vitro antifungal susceptibility of fungaemia in a Spanish multicentre prospective survey. J Antimicrob Chemother. 2012;67:1181–7.PubMedCrossRef
28.
Zurück zum Zitat Zhang XB, Yu SJ, Yu JX, Gong YL, Feng W, Sun FJ. Retrospective analysis of epidemiology and prognostic factors for candidemia at a hospital in China, 2000–2009. Jpn J Infect Dis. 2012;65:510–5.PubMedCrossRef Zhang XB, Yu SJ, Yu JX, Gong YL, Feng W, Sun FJ. Retrospective analysis of epidemiology and prognostic factors for candidemia at a hospital in China, 2000–2009. Jpn J Infect Dis. 2012;65:510–5.PubMedCrossRef
29.
Zurück zum Zitat Boonyasiri A, Jearanaisilavong J, Assanasen S. Candidemia in Siriraj hospital: epidemiology and factors associated with mortality. J Med Assoc Thai. 2013;96:S91–7.PubMed Boonyasiri A, Jearanaisilavong J, Assanasen S. Candidemia in Siriraj hospital: epidemiology and factors associated with mortality. J Med Assoc Thai. 2013;96:S91–7.PubMed
30.
Zurück zum Zitat Chen PY, Chuang YC, Wang JT, Sheng WH, Yu CJ, Chu CC, Hsueh PR, Chang SC, Chen YC. Comparison of epidemiology and treatment outcome of patients with candidemia at a teaching hospital in Northern Taiwan, in 2002 and 2010. J Microbiol Immunol Infect. 2012;. doi:10.1016/j.jmii.2012.08.025. Chen PY, Chuang YC, Wang JT, Sheng WH, Yu CJ, Chu CC, Hsueh PR, Chang SC, Chen YC. Comparison of epidemiology and treatment outcome of patients with candidemia at a teaching hospital in Northern Taiwan, in 2002 and 2010. J Microbiol Immunol Infect. 2012;. doi:10.​1016/​j.​jmii.​2012.​08.​025.
31.
Zurück zum Zitat Kothari A, Sagar V. Epidemiology of Candida bloodstream infections in a tertiary care institute in India. Indian J Med Microbiol. 2009;27:171–2.PubMedCrossRef Kothari A, Sagar V. Epidemiology of Candida bloodstream infections in a tertiary care institute in India. Indian J Med Microbiol. 2009;27:171–2.PubMedCrossRef
32.
Zurück zum Zitat Lagrou K, Verhaegen J, Peetermans WE, De Rijdt T, Maertens J, Van Wijngaerden E. Fungemia at a tertiary care hospital: incidence, therapy, and distribution and antifungal susceptibility of causative species. Eur J Clin Microbiol Infect Dis. 2007;26:541–7.PubMedCrossRef Lagrou K, Verhaegen J, Peetermans WE, De Rijdt T, Maertens J, Van Wijngaerden E. Fungemia at a tertiary care hospital: incidence, therapy, and distribution and antifungal susceptibility of causative species. Eur J Clin Microbiol Infect Dis. 2007;26:541–7.PubMedCrossRef
33.
Zurück zum Zitat Ge YP, Boekhout T, Zhan P, Lu GX, Shen YN, Li M, Shao HF, Liu WD. Characterization of the Candida parapsilosis complex in East China: species distribution differs among cities. Med Mycol. 2012;50:56–66.PubMedCrossRef Ge YP, Boekhout T, Zhan P, Lu GX, Shen YN, Li M, Shao HF, Liu WD. Characterization of the Candida parapsilosis complex in East China: species distribution differs among cities. Med Mycol. 2012;50:56–66.PubMedCrossRef
34.
Zurück zum Zitat da Silva Ruiz L, Khouri S, Hahn RC, da Silva EG, de Oliveira VK, Gandra RF, Paula CR. Candidemia by species of the Candida parapsilosis complex in children’s hospital: prevalence, biofilm production and antifungal susceptibility. Mycopathologia. 2013;175:231–9.CrossRef da Silva Ruiz L, Khouri S, Hahn RC, da Silva EG, de Oliveira VK, Gandra RF, Paula CR. Candidemia by species of the Candida parapsilosis complex in children’s hospital: prevalence, biofilm production and antifungal susceptibility. Mycopathologia. 2013;175:231–9.CrossRef
35.
Zurück zum Zitat Messer SA, Moet GJ, Kirby JT, Jones RN. Activity of contemporary antifungal agents, including the novel echinocandin anidulafungin, tested against Candida spp., Cryptococcus spp., and Aspergillus spp.: report from the SENTRY Antimicrobial Surveillance Program (2006 to 2007). J Clin Microbiol. 2009;47:1942–6.PubMedCentralPubMedCrossRef Messer SA, Moet GJ, Kirby JT, Jones RN. Activity of contemporary antifungal agents, including the novel echinocandin anidulafungin, tested against Candida spp., Cryptococcus spp., and Aspergillus spp.: report from the SENTRY Antimicrobial Surveillance Program (2006 to 2007). J Clin Microbiol. 2009;47:1942–6.PubMedCentralPubMedCrossRef
36.
Zurück zum Zitat Espinel-Ingroff A, Arendrup MC, Pfaller MA, Bonfietti LX, Bustamante B, Canton E, Chryssanthou E, Cuenca-Estrella M, Dannaoui E, Fothergill A, Fuller J, Gaustad P, Gonzalez GM, Guarro J, Lass-Flörl C, Lockhart SR, Meis JF, Moore CB, Ostrosky-Zeichner L, Pelaez T, Pukinskas SR, St-Germain G, Szeszs MW, Turnidge J. Interlaboratory variability of caspofungin MICs for Candida spp. using CLSI and EUCAST methods: should the clinical laboratory be testing this agent? Antimicrob Agents Chemother. 2013;57:5836–42. doi:10.1128/AAC.01519-13.PubMedCrossRef Espinel-Ingroff A, Arendrup MC, Pfaller MA, Bonfietti LX, Bustamante B, Canton E, Chryssanthou E, Cuenca-Estrella M, Dannaoui E, Fothergill A, Fuller J, Gaustad P, Gonzalez GM, Guarro J, Lass-Flörl C, Lockhart SR, Meis JF, Moore CB, Ostrosky-Zeichner L, Pelaez T, Pukinskas SR, St-Germain G, Szeszs MW, Turnidge J. Interlaboratory variability of caspofungin MICs for Candida spp. using CLSI and EUCAST methods: should the clinical laboratory be testing this agent? Antimicrob Agents Chemother. 2013;57:5836–42. doi:10.​1128/​AAC.​01519-13.PubMedCrossRef
37.
Zurück zum Zitat Spanu T, Posteraro B, Fiori B, D’Inzeo T, Campoli S, Ruggeri A, Tumbarello M, Canu G, Trecarichi EM, Parisi G, Tronci M, Sanguinetti M, Fadda G. Direct MALDI-TOF mass spectrometry assay of blood culture broths for rapid identification of Candida species causing bloodstream infections: an observational study in two large microbiology laboratories. J Clin Microbiol. 2012;50:176–9.PubMedCentralPubMedCrossRef Spanu T, Posteraro B, Fiori B, D’Inzeo T, Campoli S, Ruggeri A, Tumbarello M, Canu G, Trecarichi EM, Parisi G, Tronci M, Sanguinetti M, Fadda G. Direct MALDI-TOF mass spectrometry assay of blood culture broths for rapid identification of Candida species causing bloodstream infections: an observational study in two large microbiology laboratories. J Clin Microbiol. 2012;50:176–9.PubMedCentralPubMedCrossRef
39.
Zurück zum Zitat Iriart X, Lavergne RA, Fillaux J, Valentin A, Magnaval JF, Berry A, Cassaing S. Routine identification of medical fungi by the new Vitek MS matrix-assisted laser desorption ionization-time of flight system with a new time-effective strategy. J Clin Microbiol. 2012;50:2107–10.PubMedCentralPubMedCrossRef Iriart X, Lavergne RA, Fillaux J, Valentin A, Magnaval JF, Berry A, Cassaing S. Routine identification of medical fungi by the new Vitek MS matrix-assisted laser desorption ionization-time of flight system with a new time-effective strategy. J Clin Microbiol. 2012;50:2107–10.PubMedCentralPubMedCrossRef
40.
Zurück zum Zitat Kurzmann CP, Fell JW, Boekhout T. The yeasts: a taxonomic study. 5th ed. Amsterdam: Elsevier; 2011. Kurzmann CP, Fell JW, Boekhout T. The yeasts: a taxonomic study. 5th ed. Amsterdam: Elsevier; 2011.
Metadaten
Titel
Epidemiology of candidemia in Qatar, the Middle East: performance of MALDI-TOF MS for the identification of Candida species, species distribution, outcome, and susceptibility pattern
verfasst von
S. J. Taj-Aldeen
A. Kolecka
R. Boesten
A. Alolaqi
M. Almaslamani
P. Chandra
J. F. Meis
T. Boekhout
Publikationsdatum
01.04.2014
Verlag
Springer Berlin Heidelberg
Erschienen in
Infection / Ausgabe 2/2014
Print ISSN: 0300-8126
Elektronische ISSN: 1439-0973
DOI
https://doi.org/10.1007/s15010-013-0570-4

Weitere Artikel der Ausgabe 2/2014

Infection 2/2014 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.